• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    4/18/23 1:14:58 PM ET
    $AIU
    $ALLR
    $ANGN
    $AXLA
    Other Consumer Services
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIU alert in real time by email

    Gainers

    • Glory Star New Media Group Holdings Limited (NASDAQ:GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional investors at $2.48 per share.
    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares gained 108% to $3.29 after jumping 25% on Monday.
    • BELLUS Health Inc. (NASDAQ:BLU) shares jumped 99.5% to $14.48 after GSK announced it will acquire the company for $14.75 per share in cash, representing an approximate total equity value of $2 billion.
    • SAB Biotherapeutics, Inc. (NASDAQ:SABS) rose 79% to $1.38. The FDA granted Breakthrough Therapy Designation (BTD) to SAB Biotherapeutics SAB-176, an investigational therapy for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including antiviral resistant strains.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) gained 57.7% to $4.73 after the company reported key first quarter milestone achievements for drug discovery.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) gained 55% to $1.84.
    • Super League Gaming, Inc. (NASDAQ:SLGG) surged 39% to $0.5949 after the company and LandVault announced a strategic partnership to provide brands with scalable solutions to bridge the gap between Web2 and Web3.
    • Phio Pharmaceuticals Corp. (NASDAQ:PHIO) rose 38.3% to $8.13. Phio presented preclinical data showing synergy-enhanced in vivo anti-tumor efficacy of PD-1/CTLA-4 dual-targeting INTASYL.
    • Gamida Cell Ltd. (NASDAQ:GMDA) climbed 33% to $1.49 after the U.S. Food and Drug Administration approved Gamida Cell’s allogeneic cell therapy, Omisirge® (omidubicel-onlv).
    • Toro Corp. (NASDAQ:TORO) gained 29.4% to $4.2344.
    • YS Biopharma Co., Ltd. (NASDAQ:YS) gained 26% to $1.99 after the company reported preliminary total revenue of $103 million, representing a year-over-year growth of 30%.
    • Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) shares gained 25% to $4.8212.
    • Trevi Therapeutics, Inc. (NASDAQ:TRVI) surged 17.1% to $2.1550. Needham reiterated Trevi Therapeutics with a Buy and maintained an $8 price target.
    • Stronghold Digital Mining, Inc. (NASDAQ:SDIG) rose 16.4% to $1.1412.
    • Angion Biomedica Corp. (NASDAQ:ANGN) gained 15.1% to $0.7447.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) climbed 15% to $0.3221 after gaining around 18% on Monday. Bed Bath & Beyond recently filed preliminary prospectus for resale of up to 111.7 million shares of common stock by B. Riley Principal Capital II.
    • CleanSpark, Inc. (NASDAQ:CLSK) surged 11.3% to $4.8900 after gaining over 6% on Monday. CleanSpark recently announced the purchase of 45,000 units of the Antminer S19 XP bitcoin mining machines.
    • LegalZoom.com, Inc. (NASDAQ:LZ) gained 10.9% to $10.25. JMP Securities upgraded LegalZoom.com from Market Perform to Market Outperform and announced a $14 price target.
    • Sibanye Stillwater Limited (NYSE:SBSW) rose 10.7% to $9.52.
    • Axcella Health Inc. (NASDAQ:AXLA) rose 10.4% to $0.4001.
    • Altamira Therapeutics Ltd. (NASDAQ:CYTO) gained 10.3% to $1.22. Altamira Therapeutics recently announced the publication of results from its Phase 2 trial with AM-125 in acute vestibular syndrome in a leading peer reviewed journal.
    • Riot Platforms, Inc. (NASDAQ:RIOT) rose 9.8% to $14.21 amid rise in Bitcoin prices.
    • The Lion Electric Company (NYSE:LEV) gained 9% to $2.15.

    Losers

    • China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) shares fell 73.7% to $1.2499 after the company announced a $7 million registered direct offering.
    • United Insurance Holdings Corp. (NASDAQ:UIHC) fell 54.6% to $1.58. United Insurance, last month, posted a Q4 loss of $6.33 per share.
    • Blackboxstocks Inc. (NASDAQ:BLBX) fell 28% to $3.94. Blackboxstocks shares jumped 106% on Monday after the company announced it entered a letter of intent to merge with Evtec.
    • Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) fell 26.4% to $0.4201 after jumping around 103% on Monday. Bellicum Pharmaceuticals recently discontinued Phase 1/2 trials and initiated an evaluation of strategic alternatives.
    • Presto Automation Inc. (NASDAQ:PRST) fell 26.4% to $2.67 after jumping over 158% on Monday. Presto recently promoted Dan Mosher to President and Xavier Casanova to Chief Operating Officer.
    • ContraFect Corporation (NASDAQ:CFRX) shares dropped 24.9% to $1.7207 after surging 154% on Monday. ContraFect recently announced initiation of a Phase 1b/2 study of exebacase in patients with chronic prosthetic joint infections of the knee.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) fell 24.4% to $0.0361.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) dropped 22.6% to $2.8250.
    • Meta Data Limited (NASDAQ:AIU) fell 20.4% to $1.0020.
    • CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) fell 20% to $2.20 after surging 17% on Monday.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) fell 17.5% to $1.22 following Q4 results. Digital Brands Group posted a Q4 loss of $20.46 per share.
    • Evaxion Biotech A/S (NASDAQ:EVAX) fell 17.3% to $1.4399. Evaxion Biotech presented data from its Phase 1/2A study of its DNA-based personalized cancer immunotherapy, EVX-02 in combination with the checkpoint inhibitor nivolumab at the 2023 AACR Meeting.
    • KWESST Micro Systems Inc. (NASDAQ:KWE) fell 17.4% to $2.55 after gaining 18% on Monday.
    • Kiromic BioPharma, Inc. (NASDAQ:KRBP) dropped 14.7% to $4.09.
    • Windtree Therapeutics, Inc. (NASDAQ:WINT) fell 13.6% to $7.15. Windtree Therapeutics shares surged 91% on Monday after the company announced the European Patent Office has granted Patent No. 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
    • AEye, Inc. (NASDAQ:LIDR) shares fell 11.7% to $0.2825 after climbing 35% on Monday.
    • Relay Therapeutics, Inc. (NASDAQ:RLAY) dropped 11.5% to $16.12.
    • Merus N.V. (NASDAQ:MRUS) fell 10.8% to $21.35.
    • FiscalNote Holdings, Inc. (NYSE:NOTE) dropped 10.3% to $2.42.
    • Oblong, Inc. (NASDAQ:OBLG) fell 8.2% to $1.9637 after dropping more than 20% on Monday.
    • Telefonaktiebolaget LM Ericsson (publ) (NASDAQ:ERIC) dropped 7.2% to $5.49 after the company reported Q1 financial results. The company also announced CFO Carl Mellander will step down at the end of the Q1 2024.

    Now Read This: Wall Street's Most Accurate Analysts Say Sell These 3 Tech Stocks Delivering High-Dividend Yields

    Get the next $AIU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIU
    $ALLR
    $ANGN
    $AXLA

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Ericsson
    $ERIC
    2/9/2026$11.00Equal-Weight
    Morgan Stanley
    Relay Therapeutics Inc.
    $RLAY
    1/26/2026$14.00Perform → Outperform
    Oppenheimer
    D/B/A Sibanye-Stillwater Limited
    $SBSW
    1/23/2026$24.80Hold → Buy
    HSBC Securities
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    CleanSpark Inc.
    $CLSK
    1/13/2026$22.50Outperform
    Northland Capital
    CleanSpark Inc.
    $CLSK
    1/8/2026$22.00Buy
    Maxim Group
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    More analyst ratings

    $AIU
    $ALLR
    $ANGN
    $AXLA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 6, 2024 - FDA Roundup: December 6, 2024

    For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

    12/6/24 3:09:02 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIU
    $ALLR
    $ANGN
    $AXLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Ericsson with a new price target

    Morgan Stanley initiated coverage of Ericsson with a rating of Equal-Weight and set a new price target of $11.00

    2/9/26 8:15:00 AM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Relay Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00

    1/26/26 8:32:07 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIU
    $ALLR
    $ANGN
    $AXLA
    SEC Filings

    View All

    SEC Form S-8 filed by CNS Pharmaceuticals Inc.

    S-8 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    2/27/26 5:22:40 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    2/27/26 4:45:16 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Blackboxstocks Inc.

    144 - REALLOYS INC. (0001567900) (Subject)

    2/26/26 7:34:26 PM ET
    $BLBX
    EDP Services
    Technology

    $AIU
    $ALLR
    $ANGN
    $AXLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF LEGAL OFFICER Miller Nicole sold $154,645 worth of shares (23,325 units at $6.63), decreasing direct ownership by 3% to 813,033 units (SEC Form 4)

    4 - LEGALZOOM.COM, INC. (0001286139) (Issuer)

    2/27/26 6:28:40 PM ET
    $LZ
    EDP Services
    Technology

    SEC Form 4 filed by Chief Development Officer Cassella James V

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    2/20/26 4:17:06 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Galletta Christopher

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    2/20/26 4:16:45 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIU
    $ALLR
    $ANGN
    $AXLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/29/25 5:16:48 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIU
    $ALLR
    $ANGN
    $AXLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

    Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026 Approximately $555 million in cash, cash equivalents and investments at end of Q4 2025 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and gen

    2/26/26 4:05:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    U.S. shows ISAC leadership as Ericsson demonstrates breakthrough drone detection proof of concept at Texas headquarters

    The proof of concept integrates sensing and spatial location of passive objects into mobile networks, proving 5G technology's ability to sense its surroundings using telecommunications infrastructureWide-area network sensing augments local sensors for UAV/airspace safety, transportation assistance, and industrial protection, and can enhance network performanceEricsson's ISAC (Integrated Sensing and Communication) technology creates opportunities for commercial, public safety and defense use cases across the industryPLANO, Texas, Feb. 26, 2026 /PRNewswire/ -- Ericsson today announced a successful live proof of concept of its ISAC (Integrated Sensing and Communication) technology at the compan

    2/26/26 9:45:00 AM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    NTT DATA and Ericsson Team Up to Scale Private 5G and Physical AI for Enterprises

    Private 5G delivered as a fully managed global service with consistent security and operations worldwide Edge AI and physical AI embedded directly into enterprise connectivity for real-time, autonomous decision-making Together, the companies help enterprises move from pilots to globally scalable, production-ready solutions NTT DATA, a global leader in AI, digital business and technology services, and Ericsson (NASDAQ:ERIC) today announced a multi-year strategic partnership to accelerate enterprise adoption of private 5G and unlock advanced edge AI and physical AI use cases. As organizations look to embed intelligence at the edge across global operations, the partnership will enabl

    2/26/26 8:00:00 AM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $AIU
    $ALLR
    $ANGN
    $AXLA
    Leadership Updates

    Live Leadership Updates

    View All

    Blackboxstocks Inc. (NASDAQ: BLBX) Merger Target, REalloys to Appoint Bob Foresman to its Board of Directors

    Following the Addition of General Jack Keane, REalloys Further Strengthens Board with Addition of Former Vice Chairman of UBS Investment Bank  Blackboxstocks/REalloys Form S-4 has been declared effective by the SEC, and, pending NASDAQ listing approval, the company expects to close the merger DALLAS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ:BLBX) ("Blackboxstocks" or the "Company") today announced that its merger target, REalloys Inc. ("REalloys"), has entered into a designate director agreement with Bob Foresman. Mr. Foresman will formally join the REalloys Board of Directors upon the closing of the merger between Blackboxstocks and REalloys. Blackboxstocks' regist

    2/18/26 8:00:00 AM ET
    $BLBX
    EDP Services
    Technology

    Global technology leaders launch Trusted Tech Alliance

    In a time when the world is divided, 15 leading global companies from 10 countries are coming together to serve customers around the worldSTOCKHOLM, Feb. 13, 2026 /PRNewswire/ -- Today, at the Munich Security Conference, 15 companies from Africa, Asia, Europe, and North America announced the launch of the Trusted Tech Alliance (TTA), a group of likeminded global technology providers coming together to work across borders, and based on a shared set of principles for a trusted technology stack – from connectivity, cloud infrastructure, and semiconductors to software and AI. These principles are designed to ensure that, regardless of a supplier's nationality, companies in this Alliance will ad

    2/13/26 12:29:00 PM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Blackboxstocks Inc. (NASDAQ: BLBX) Merger Target REalloys, to Appoint General Jack Keane to its Board of Directors

    General Keane, a Four-Star General (Ret), Joins REalloys on its Mission to Scale North-America's Most Advanced Heavy Rare Earth Supply Chain & Technology Platform REalloys' Form S-4 has been declared effective by the SEC, and, pending NASDAQ listing approval, the company expects to close its merger with Blackboxstocks, Inc. (NASDAQ:BLBX) DALLAS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ:BLBX) ("Blackboxstocks" or the "Company") today announced that its merger target, REalloys Inc. ("REalloys"), has appointed General John M. "Jack" Keane (U.S. Army, Ret.) as a Designate Director. General Keane will formally join the Board of Directors upon the closing of the merger b

    2/9/26 8:30:00 AM ET
    $BLBX
    EDP Services
    Technology

    $AIU
    $ALLR
    $ANGN
    $AXLA
    Financials

    Live finance-specific insights

    View All

    Blackboxstocks and REalloys Announce Closing of Merger; REalloys to Begin Trading on Nasdaq Under Ticker "ALOY"

    DALLAS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ:BLBX) ("Blackboxstocks") today announced the successful closing of its previously announced merger with REalloys Inc. ("REalloys") following the close of market on February 24, 2026. Effective at the open of trading on Wednesday, February 25, 2026, the combined company will operate under the name REalloys Inc. and its common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol "ALOY." The transaction marks the public market debut of a vertically integrated North American heavy rare earth platform focused on establishing a secure, zero-China nexus supply chain aligned with U.S. defense procure

    2/24/26 5:42:09 PM ET
    $BLBX
    EDP Services
    Technology

    Bed Bath & Beyond, Inc. Reports Eighth Consecutive Quarter of Measurable Improvement Toward Profitability

    Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio

    2/23/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    AEye to Report 2025 Fourth Quarter and Full Year Results on Monday, March 16 and Host Conference Call and Webcast

    AEye, Inc. (NASDAQ:LIDR), a global leader in software-defined, high-performance lidar solutions, today announced that it will release its 2025 fourth quarter and full year financial results, after market close on Monday, March 16, 2026. A conference call and webcast will be held on the same day, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). During the call, AEye CEO Matt Fisch and CFO Conor Tierney will review the company's financial results and provide a business update, followed by a question-and-answer session. Supplemental financial information will be available on the company's website prior to the conference call. The live webcast of the call with an accompanying slide prese

    2/23/26 11:00:00 AM ET
    $LIDR
    Auto Parts:O.E.M.
    Consumer Discretionary

    $AIU
    $ALLR
    $ANGN
    $AXLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 7:15:44 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/14/24 5:51:58 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KWESST Micro Systems Inc.

    SC 13G - KWESST Micro Systems Inc. (0001889823) (Subject)

    11/14/24 5:34:02 PM ET
    $KWE
    Computer Software: Prepackaged Software
    Technology